# Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

> **NCT02876640** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage IB Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Breast Ductal Carcinoma In Situ
- Early Stage Breast Carcinoma
- Invasive Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Retinoid 9cUAB30
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT02876640
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-16
- **Primary completion:** 2022-06-03
- **Final completion:** 2022-06-03
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Inadequate Accrual Rate
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876640, "Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02876640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*